Eficácia e segurança dos antipsicóticos atípicos (quetiapina, risperidona, aripiprazol, paliperidona) em comparação com um placebo ou medicamentos antipsicóticos típicos no tratamento da esquizofrenia refratária
overview de revisão sistemática
Palavras-chave:
Esquizofrenia, Agentes antipsicóticos, Antagonistas de dopamina, Risperidona, RevisãoResumo
CONTEXTO E OBJETIVO: De acordo com alguns estudos de coorte, a prevalência da esquizofrenia refratária (ER) está entre 20-40%. Nosso objetivo foi avaliar a efetividade e segurança de aripiprazol, paliperidona, quetiapina e risperidona no tratamento da esquizofrenia refratária. MÉTODOS: Avaliação crítica das revisões Cochrane publicadas na Biblioteca Cochrane e complementação com referências de ensaios clínicos randomizados (ECRs) mais atualizados sobre ER. As seguintes bases de dados foram pesquisadas: Medline (Medical Literature Analysis and Retrieval System Online) (1966-2009), Ensaios Controlados da Colaboração Cochrane (2009, edição 2), Embase (Excerpta Database) (1980-2009), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde) (1982-2009). Não houve restrição a idiomas. Ensaios clínicos randomizados, revisões sistemáticas e metanálises que avaliaram antipsicóticos atípicos no tratamento da esquizofrenia refratária foram incluídos. RESULTADOS: Sete revisões sistemáticas Cochrane e 10 ECRs complementares foram incluídos nessa revisão. No geral os dados demonstram pequenas diferenças entre os antipsicóticos atípicos avaliados e os típicos na melhora dos sintomas da doença, apesar da melhor adesão ao tratamento com os atípicos. A risperidona foi avaliada especificamente em pacientes com esquizofrenia refratária em uma das revisões sistemáticas incluídas, a qual demonstrou desfechos favoráveis, porém não definitivos quando comparada a drogas também com eficácia comprovada como amisulprida, clozapina e olanzapina. CONCLUSÕES: Os dados reforçam a dificuldade de tratar esses pacientes, com elevadas taxas de desistência do tratamento e padrões de melhora modestos nas avaliações de eficácia. Os antipsicóticos atípicos têm vantagens sobre os típicos principalmente pelo melhor perfil de segurança, o que leva a melhor adesão ao tratamento. A associação de antipsicóticos também pode ser uma opção em alguns pacientes refratários ao tratamento.
Downloads
Referências
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15- year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85.
Barnes TRE, Buckley P, Schulz SC. Treatment-resistant schizophrenia. In: Hirsch SR, Weinber- ger D, editors. Schizophrenia. 2nd ed. Oxford: Blackwell Publishing; 2003. p. 489-516.
Altamura AC, Bassetti R, Cattaneo E, Vismara S. Some biological correlates of drug resis- tance in schizophrenia: a multidimensional approach. World J Biol Psychiatry. 2005;6 suppl 2:23-30.
Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997;154(4):475-82.
Henna J, Oliveira JR, Mello MF, et al. Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients. Schizophrenia Research. 1999;36(1-3):281-2.
National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antip- sychotic drugs for the treatment of schizophrenia. London: National Institute for Clini- cal Excellence; 2002. Available from: http://www.crd.york.ac.uk/crdweb/ShowRecord. asp?View=Full&ID=32002000858. Accessed in 2010 (Apr 29).
Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophre- nia. Schizophr Bull. 1990,16(4):551-61.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96.
El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD004578.
Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophre- nia. Cochrane Database Syst Rev. 2008;(3):CD006617.
Nussbaum AM, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;(2):CD006369.
Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Data- base Syst Rev. 2004;(2):CD000967.
Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000440.
Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antip- sychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;(3):CD002306.
Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD005237.
Moher D, Tsertsvadze A, Tricco AC, et al. When and how to update systematic reviews. Co- chrane Database Syst Rev. 2008(1) MR000023.
Carson WH, Ingenito GG, McQuade RD, Stock EG, Iwamoto T. [Schizophrenia; safety/tolera- bility of aripiprazole]. In: XIIth World Congress of Psychiatry; Aug 24-29; Yokohama, Japan; 2002. [abstract].
Kane J, William HCJ, Kujawa MJ, et al. Aripiprazole vs. perphenazine in treatment-resistant schizophrenia. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA; 2003. [NR537].
Daniel DG, Stock EG, Wilber CH, et al. Intramuscular aripiprazole in acutely agitated psycho- tic patients. In: 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA; 2004. [APA Conference abstracts NR612].
Oren D, Marcus R, Kostic D, et al. Efficacy and Safety of Intramuscular Aripiprazole, Halope- ridol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder. In: XX International Congress on Schizophrenia Research; 2005 April 2-6, Georgia, USA; 2005. Schizophrenia Bulletin 2005;31:399. [abstract].
Carson WH, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan; Puerto Rico; 2000. [abstract].
Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology. 2000;10(Suppl 3):S309-10.
Csernansky JG. Treatment of schizophrenia: preventing the progression of disease. Psychiatr Clin North Am. 2003;26(2):367-79.
Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsycho- tic: overview of a phase II study result. International Journal of Neuropsychopharmacology. 2000;3(Suppl 1):S157.
Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1): S186.
Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-31.
Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213-23.
Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperido- ne extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo- controlled study. Schizophr Res. 2007;93(1-3):117-30.
Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for preven- tion of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6-14.
Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-relea- se tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-70.
Tzimos A, Kramer M, Ford L, et al. A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. In: 25th Collegium Internationale Neuro-psychopharma- cologicum; 2006, Jul 9-13; Chicago, Illinois; 2006. [abstract]
Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone ex- tended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat. 2008;4(5):949-58.
Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizo- phrenia. Am J Psychiatry. 2009;166(6):691-701.
Hirsch S, Arvanitis L, Miller B, Smith A. A multicentre, double-blind, placebo-controlled com- parison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. European Neurop- sychopharmacology. 1994;4(3):384-5.
Link CGG, Arvanitis L. ‘Seroquel’ treatment of hospitalised patients with acute exacerba- tion of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double- blind comparison of low and high dosage regimens. European Neuropsychopharmacology 1995;5:346-7.
Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophre- nia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54(6):549-57.
Addington DE, Arvanitis LA. ‘Seroquel’ (quetiapine): an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study. In: 4th International Conference on Schi- zophrenia 1996: Breaking Down the Barriers; 1996, Oct 6-9; Vancouver, Canada; 1996. [abstract].
Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. European Neuropsychopharmacology. 1996;6(Suppl 3):148.
Arvanitis LA, Miller BG. Quetiapine, an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study. In: 149th Annual Meeting of American Psychiatric Associa- tion; 1996, May 2-9, New York, New York; 1996. [abstract].
Arvanitis LA, Miller BG, Kowalcyk BB. Efficacy of ‘Seroquel’ (Quetiapine Fumarate) in affecti- ve symptoms of schizophrenia. In: 36th Annual Meeting of the American College of Neurop- sychopharmacology; 1997, Dec 8-12, Waikoloa, Hawaii; 1997. [abstract].
Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-46.
Arvanitis LA, Miller BG, Study Group. ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial. Psychopharmacology Bulletin. 1966;32:391.
Borison RL, Arvanitis LA, Miller BG. A comparison of five fixed doses of ‘seroquel’ (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Re- search. 1996;18(2-3):132.
Borison RL, Arvanitis LA, Miller BG. A multiple fixed-dose, placebo-controlled trial with ‘sero- quel’ - An atypical antipsychotic. Biological Psychiatry. 1996;39(7):597-8.
Cantillon M. Quetiapine fumarate reduces aggression. In: 11th Annual Meeting of the Ame- rican Association for Geriatric Psychiatry; 1998, Mar 8-11, San Diego, California; 1998. [abstract].
Cantillon M, Goldstein JM. Efficacy of quetiapine fumarate in affective symptoms of schi- zophrenia. In: 151st Annual Meeting of the American Psychiatric Association; 1998, May 30 – Jun 4, Toronto, Ontario; 1998. [abstract].
Cantillon M, Goldstein JM. Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia. In: 151st Annual Meeting of the American Psychiatric Association; 1998, May 30 – Jun 4, Toronto, Ontario; 1998. [abstract].
Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): not different from placebo for EPS or prolactin. Biological Psychiatry. 1996;39:598.
Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. European Neuropsychopharmacology. 1996;6(Suppl 3):171.
Hong WW, Arvanitis LA, Miller BG. Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome or effect on plasma prolactin. In: 149th Annual Meeting of the American Psychiatric Association; 1996, May 2-9, New York, New York; 1996. [abstract].
Hong WW, Miller BG, Arvanitis LA. The atypical profile of ‘Seroquel’ (ICI 204,636) is suppor- ted by the lack of sustained elevation of plasma prolactin in schizophrenic patients. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11-15, San Juan, Puerto Rico; 1995. [abstract].
Fabre LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indica- tion of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17(3):366-78.
Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psycho- pharmacol. 1996;16(2):158-69.
Arvanitis L, Miller B, Fennimore J. A multicentre, placebo-controlled double-blind evaluation of SeroquelTM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. European Neuropsychopharmacology. 1994;4(3):385.
Link CGG, Arvanitis L. SeroquelTM treatment of hospitalised patients with acute exacerba- tion of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double- blind comparison of low and high dosage regimens. European Neuropsychopharmacology. 1995;5(3):346-7.
Barzega G, Bogetto F, Maina G, Ravizza L. [Efficacia e tollerabilita dell’ antipsychotico atipico quetiapina: uno studio in doppio cieco]. Minerva Psichiatrica 1999;40:297-305.
Barzega G, Bogetto F, Maina G, Ravizza L. Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison. European Journal of Psychiatry 2000;14:221-32.
Fleischhacker WW, Link CCG, Horne B. A multicentre, double-blind, randomised comparison of dose and dose regimen of ‘Seroquel’ in the treatment of patients with schizophrenia. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11- 15, San Juan, Puerto Rico; 1995. [abstract].
King DJ, Link CGC. ‘Seroquel’ (ICI 204636): an atypical antipsychotic - results from Phase
III. European Neuropsychopharmacology 1996;6:202.
King DJ, Link CGG. Seroquel (ICI 204636): an atypical antipsychotic results from Phase
III. In: XXth Collegium Internationale Neuro-psychopharmacologicum; 1996, June 23-27, Melbourne, Australia; 1996. [abstract].
King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Se- roquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998;137(2):139- 46.
Reuther E, Degner D. Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 (‘Seroquel’). Nervenarzt 1996;67:S192.
Purdon SE, Malla A, Labelle A, Litt W. Long-term treatment of quetiapine improves cognitive function in schizophrenia. Biological Psychiatry. 2000;47(8 Suppl 1):S42.
Purdon SE, Malla A, Labelle A, Litt W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26(2):137-49.
Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95-105.
Fleishhacker W, Link C, Hurst B. ICI 204,636 (Seroquel) - a putative new antipsychotic: results from Phase III trials. Schizophrenia Research 1996;18:32.
Hellewell JSE, Hurst BC, Link CGG. Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic (‘Seroquel’-ICI 204,636). European Neuropsychopharmacolo- gy 1996;6:123.
Link C, Farrow L. ‘Seroquel’™ (ICI 204, 636) EPS and prolactin - comparison with halo- peridol. In: 10th World Congress of Psychiatry; 1996, Aug 23-28, Madrid, Spain; 1996. [abstract].
Empfield JR, Clayton J, Isaac M, et al. AstraZeneca AB. Metabotropic glutamate receptor-po- tentiating isoindolones. [Patent application]. Available from: http://www.faqs.org/patents/ app/20090149505. Accessed in 2010 (May 27).
Link C, Smith A, Miller B, Ryan J, Study Group. A multicentre, double-blind, controlled compa- rison of SeroquelTM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. European Neuropsychopharmacolo- gy. 1994;4(3):385.
Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96(4):265-73.
Buckley PF, Goldstein JM, Emsley RA. Comparison of quetiapine and haloperidol in treat- ment-resistant schizophrenia. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
Emsley RA, Bailey P, Jones AM, Raniwalla JTI. Efficacy of quetiapine fumarate in partial responders. In: Annual Meeting of the American Psychiatry Association; 1999, Washington, USA; 1999. [abstract].
Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizo- phrenia: efficacy of quetiapine versus haloperidol. European Neuropsychopharmacology 2001;11:S264.
Emsley RA, Raniwalla J, Bailey P, Jones AM. [Efficacy and tolerability of ‘Seroquel’ compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment]. European Neuropsychopharmacology. 1999;9(Suppl 5):S267.
Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstra- ted, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000;15(3):121-31.
Emsley RA, Raniwalla J, Jones AM, PRIZE Study Group. Efficacy of seroquel in trea- ting all of the positive and negative symptoms of schizophrenia. Schizofrenia Research. 2000;41(1):203.
Goldstein JM, Buckley P. Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan, Puerto Rico; 2000. [abstract].
Nasrallah HA, Rennie P, Altman C. Patterns of response in patients with schizophrenia par- tially responsive to fluphenazine and switched to quetiapine or haloperidol. European Neu- ropsychopharmacology. 2001;11(Suppl 3):S262.
Weiden PJ, Ashworth P. Switching from fluphenazine to quetiapine ameliorates extrapyrami- dal symptoms and neuroendocrine side effects in patients with schizophrenia. European Neuropsychopharmacology. 2001;11(Suppl 3):S262-S263.
Kudo Y, Nomura J, Ikawa G, et al. Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control. Rinsyo Iyaku. 2000;16:1807-42.
Kudo Y, Nomura J, Ikawa G, et al. Clinical trial of quetiapine in schizophrenia - efficacy and tolerability of quetiapine: a comparative double-blind study with masopramine in schizo- phrenic patients. In: Annual Meeting of the World Psychiatric Association; 1999, Aug 6-11; Hamburg, Germany; 1999. [abstract].
Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolera- bility of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839-54.
Tandon R. Quetiapine and risperidone in outpatients with schizophrenia: subanalysis of the QUEST trial. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005;28(4):163-8.
Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetia- pine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24(1):1-13.
Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, ha- loperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16(1):38-44.
Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25-40.
Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chro- nic schizophrenic inpatients: a multicentre double-blind comparitive study. Acta Psychiatr Scand. 1992;85(4):295-305.
Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treat- ment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88(6):395-402.
Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the tre- atment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995;91(4):271-7.
Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-35.
Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993;34(2):179-90.
Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi- national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166(6):712-26; discussion 727-33.
Potkin SG, Gutierrez R. In: 150th Annual Meeting of the American Psychiatric Association; 1997, May 17-22; San Diego, California; 1997. [abstract].
Bouchard RH, Demers MF, Merette C, Pourcher E. Classical neuroleptics (CNLP) vs risperdo- ne (RIS) interim 12 months efficacy of a long-term, naturalistic study in schizophrenics. In: 11th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
Mahmoud RA, Engelhart LM, Risperidone Outcome Study of Effectiveness (ROSE) Group Janssen Research Foundation. Risperidone versus conventional antipsychotics in usual care: a prospective randomised effectiveness trial of outcomes for patients with schizo- phrenia and schizoaffective disorder. In: 11th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
Namjoshi M, Young C, Huang L, Edgell ET, Breier A. Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizo- phrenia: results from a US random study. International Journal of Neuropsychopharmacolo- gy In: 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002, Jun 23-27; Montreal, Canada; 2002. [abstract].
Namjoshi M, Young Cm, Huang L, Edgell ET, Breier A. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol. 2002;(Suppl 3): S315.
Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olan- zapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765-74.
Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11(6):638-47.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus rispe- ridone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychophar- macol. 1997;17(5):407-18.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81(1):1-15.
Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophre- nia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Cana- dian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3): 249-58.
Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharma- cology. 2003;28(1):182-92.
Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev. 2003;(4):CD004161.
Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-32.
Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for pa- tients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperi- done for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2008;23(6):455-63.
Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90-4.
Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-23.
Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472-82.
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-63.
Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr. 2005;27(3): 178-84.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first- episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008;371(9618):1085-97.
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-57.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
